Biotech drugmaker Generex on Monday reported positive results for a mid-stage study of its experimental cancer vaccine.
The company said data after 13 months showed only half of breast cancer patients who received the company's vaccine relapsed, compared with those not taking the vaccine.
Generex will report the final results after two years of follow-up. The company is also studying the vaccine to prevent relapse in prostate cancer patients.
Shares of Generex Biotechnology Corp. rose 5 cents, or 7.8 percent, to 68 cents in afterhours trading.